Acasti Pharma Inc.  (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia.
When it came into the limelight with a $35 million Series A financing in 2018, Attenua promised to repurpose three oral neuronal nicotinic receptor assets discarded by Catalyst Biosciences (which in turn got the drugs through a merger with Targacept). But now that it’s wrapped a proof-of-concept trial of the lead drug in chronic cough, Attenua is flipping the portfolio to another buyer for yet another use.
(Reuters Health) - A large U.S. study designed to gauge the health benefits of vitamin D and fish oil supplements concludes that the omega-3 oil can dramatically reduce the odds of a heart attack while vitamin D’s benefits seem to come from lowering the risk of death from cancer.
Acasti Pharma & CordenPharma Announce Large Scale Production of CaPre with Continuous Manufacturing
Advanced Enzyme Technologies Ltd has entered into definitive agreements with API maker JC Biotech to acquire 70 per cent stake for a consideration of Rs. 50 crore.
Selling most of its API business had only a limited impact on revenues in 2015 according to BASF, which has reiterated its plan to retain its ibuprofen, PEG and omega-3 operations.